Trung Huynh
Stock Analyst at UBS
(3.61)
# 868
Out of 4,732 analysts
31
Total ratings
60.87%
Success rate
22.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Downgrades: Neutral | $1,130 → $738 | $681.58 | +8.28% | 1 | Jan 16, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $3.33 | +290.39% | 1 | Oct 10, 2024 | |
| CABA Cabaletta Bio | Initiates: Buy | $10 | $2.74 | +264.96% | 1 | Oct 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $54 | $56.29 | -4.07% | 4 | Oct 9, 2024 | |
| INSM Insmed | Maintains: Buy | $78 → $84 | $72.51 | +15.85% | 3 | Aug 9, 2024 | |
| LLY Eli Lilly | Assumes: Buy | $612 → $710 | $725.72 | -2.17% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $147.03 | +19.02% | 2 | Jul 21, 2023 | |
| AMGN Amgen | Maintains: Outperform | $220 → $200 | $272.11 | -26.50% | 3 | Jul 12, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $47 → $40 | $26.30 | +52.09% | 4 | Jun 29, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $125 → $126 | $97.92 | +28.68% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $171.56 | -0.91% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.27 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Jan 16, 2025
Downgrades: Neutral
Price Target: $1,130 → $738
Current: $681.58
Upside: +8.28%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $3.33
Upside: +290.39%
Cabaletta Bio
Oct 10, 2024
Initiates: Buy
Price Target: $10
Current: $2.74
Upside: +264.96%
Bristol-Myers Squibb Company
Oct 9, 2024
Maintains: Neutral
Price Target: $50 → $54
Current: $56.29
Upside: -4.07%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $78 → $84
Current: $72.51
Upside: +15.85%
Eli Lilly
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $725.72
Upside: -2.17%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $147.03
Upside: +19.02%
Amgen
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $272.11
Upside: -26.50%
Pfizer
Jun 29, 2023
Downgrades: Neutral
Price Target: $47 → $40
Current: $26.30
Upside: +52.09%
Merck & Co.
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $97.92
Upside: +28.68%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $171.56
Upside: -0.91%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.27
Upside: -